Poster DownloadEnglish
Poster Download日本語
Chiba University Hospital
Clinical Research Center
The REACTA Forum 2019
Registration Secretariat
c/o JTB Communication
Design, Inc.
Celestine Shiba Mitsui Bldg.
3-23-1 Shiba, Minato-ku,
Tokyo 105-8335, Japan
Tel: +81-3-5657-0708

Program※Program will be updated shortly

Opening Remarks8:25-8:30

Key note address8:30-9:00

Challenges and Opportunities in Clinical Research in East Asia
Hiromichi Shirasawa
(MSD K.K.)
白沢 博満

Session 19:00-10:40

Innovative Approaches for Clinical Trials
Recent advances in digital technology and future of “data-driven healthcare”
Takayuki Sasaki
(Office of Pharmaceutical Industry Research)
佐々木 隆之
(日本製薬工業協会 医薬産業政策研究所)
Values of Digital and RWD for Clinical Trials: Views from Pharma companies
Shinya Suda
(Astellas Pharma Inc.)
須田 真也
Learnings from a virtual trial pilot in the US
Yumiko Miyazaki
(Eli Lilly Japan K.K.)
宮崎 由美子
Engaging patients in Asia for clinical trials – the secret to success
David Yoshii
(Parexel International Corporation)
AI-Enhanced Safety of Prescriptions and Clinical Application
Alex Nguyen
(Taipei Medical University)

- Coffee Break (10:40-10:50)

Session 210:50-12:30

Regenerative Medicine
Current topics in Regenerative Medical Products
Yasuhiro Fujiwara
(Pharmaceuticals and Medical device Agency
 Office of Cellular and Tissue-based Products)
藤原 康宏
(医薬品医療機器総合機構 再生医療製品等審査部)
Regenerative medicine: Developments and market outlook in Japan
Sonoko Shiokawa
(Seed Planning, Inc.)
塩川 園子
(株式会社 シード・プランニング)
Paradigm shift of medical care by a novel reparative therapy with Muse cell
Seiichi Kiso
(Life Science Institute, Inc.)
木曽 誠一
(株式会社 生命科学インスティテュート)
Cancer immunotherapy - from basic research of NKT cell to clinical fields-
Shinichiro Motohashi
(Chiba University)
本橋 新一郎
Malaysia's Clinical Trial Guideline on Cell and Cell-based Therapies
Fadilah Abdul Wahid
(The National University of Malaysia)

- Lunch (12:30-14:00)

Session 314:00-15:20

Clinical Development / Pharmaceutical Strategy in Asia
Clinical development strategy to maximize the potential of Asia in global study
Koichi Miyazaki
(Daiichi Sankyo Co., Ltd.,)
宮崎 浩一
Key consideration of regulation for Asian clinical development
Yuko Kikuchi
(Eisai Co., Ltd.,)
菊地 優子
Investigational Drug Products for Phase 1 Studies
– Clinical Development Efficiencies through Best Practice Pharmacy Compounding
Kate Reese
(Celerion Inc.)
Global drug development and ICH E17 guideline
Yoshiaki Uyama
(Pharmaceuticals and Medical Device Agency / Chiba University)
宇山 佳明
(医薬品医療機器総合機構 / 千葉大学)

- Coffee Break (15:20-15:30)

Session 415:30-16:50

Clinical Trials in Asia
Kawasaki Disease and KAICA Trial
Hiromichi Hamada
(Tokyo Woman’s Medical University)
濱田 洋通
Current Issues about Immunologic agent clinical trials in Korea
Sung Yong Oh
(Dong-A University)
Medical Device trials in Malaysia – New opportunities
Alvin Lee
(InnoSignum SDN. BHD.)
Comparison of urinary tract infection in Asian countries
Katsumi Shigemura
(Kobe University)
重村 克巳

Session 516:50-18:10

Initiatives of Academic Research Organization
South Korea's Clinical Trial Infrastructure: Lessons learned and the way forward
Anthony Nguyen
(Dong-A University)
The Special ARO System Infrastructure of TMU to Support Pharmaceutical Industry
Shian-Ying Sung
(Taipei Medical University)
Collaboration between academia, industry and the government to catalyse clinical research in Malaysia
Audrey Ooi
(Clinical Research Malaysia)
Chiba university ARO initiative and the education of academia clinical research professional staff
Hideki Hanaoka
(Chiba University)
花岡 英紀

Closing Remarks18:10-18:15